Talphera, Inc. Announces Board Changes and Officer Compensation Updates

TL;DR

Talphera's board is changing: Lim out, Van Den Berg in. Officer pay also updated.

AI Summary

On October 14, 2025, Talphera, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company announced the departure of Director Jonathan M. J. Lim and the appointment of Dr. David J. E. J. Van Den Berg as a new director. The filing also disclosed updates to the compensatory arrangements for certain officers.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board and executive changes, along with compensation adjustments, can introduce uncertainty and signal potential strategic shifts.

Key Players & Entities

• Talphera, Inc. (company) — Registrant
• Jonathan M. J. Lim (person) — Departing Director
• David J. E. J. Van Den Berg (person) — Appointed Director
• October 14, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value TLPH The Nasdaq Capital M
• $1.11 — ur common stock at an exercise price of $1.11 per share, pursuant to our 2020 Equity

Filing Documents

• acrx20251015_8k.htm (8-K) — 30KB
• 0001437749-25-031162.txt ( ) — 162KB
• tlph-20251014.xsd (EX-101.SCH) — 3KB
• tlph-20251014_def.xml (EX-101.DEF) — 12KB
• tlph-20251014_lab.xml (EX-101.LAB) — 15KB
• tlph-20251014_pre.xml (EX-101.PRE) — 12KB
• acrx20251015_8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Director On October 14, 2025, the board of directors of Talphera, Inc. appointed Joseph Todisco as a Class III member of the board of directors and member of the compensation committee to hold office for the balance of a term expiring at our 2026 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Todisco, age 49, has served as the Chief Executive Officer of CorMedix Inc. since May 2022, and as a member of the board of directors of CorMedix Inc. since March 2022. From October 2011 to May 2022, he was a senior executive at Amneal Pharmaceuticals, where for the prior 11 years he held various roles, most notably as Executive Vice President, Chief Commercial Officer where he was responsible for Amneal Specialty, a branded specialty products business with a focus on neurology and endocrinology. He was previously Co-Founder and managing executive of Gemini Laboratories, a specialty pharmaceutical company focused on the sales and marketing for niche branded products in the U.S. Market. Gemini Laboratories was established as an affiliate of Amneal Pharmaceuticals and was subsequently acquired by Amneal in 2018. Prior to joining Amneal, Mr. Todisco was Vice President, Business Development & Licensing at Ranbaxy, Inc. Prior to Ranbaxy, he held various roles at Par Pharmaceutical, and in his earlier career held positions at Oppenheimer & Company and Marsh & McLennan Companies. Mr. Todisco obtained his M.B.A. in Finance from Fordham Graduate School of Business and his B.A. in Economics from Georgetown University. In connection with his appointment, the compensation committee approved an initial grant to Mr. Todisco, on October 15, 2025, of 6,397 restricted stock units and options to purchase 38,381 shares of our c

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 16, 2025 Talphera, Inc. By: /s/ Raffi Asadorian Name: Raffi Asadorian Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR